Abstract
Enfortumab vedotin (EV) was approved for patients with unresectable urothelial carcinoma who progressed after anti-cancer therapy on September 2021 in Japan based upon findings in the phase III EV-301 trial (NCT03474107). In the study upper tract urothelial carcinoma (UTUC) patients accounted for approximately 30% and the upper limit of hazard ratio of EV for progression-free survival was greater than 1. Therefore, we reviewed the association between response to EV therapy and primary tumor location in Japanese urothelial carcinoma patients using our real-world data.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
